DOI：10.12201/bmr.202606.00053

Synergizing Local and Systemic Therapies: Advances in Abscopal Effect-Based Strategies for Advanced Cancer

•  

  Abstract: Background: The abscopal effect, defined as tumor regression at non-irradiated or non-treated distant sites following localized therapy, represents a paradigm-shifting phenomenon in oncology with the potential to achieve "functional cure" in advanced cancers. However, spontaneous or single-modality abscopal responses remain exceedingly rare, occurring in fewer than 10% of patients across most solid tumor types. Objective: This review systematically examines the synergistic framework of "local induction plus systemic enhancement" in driving abscopal effects, encompassing the underlying immunological mechanisms, clinical evidence, and translational prospects. Methods: We conducted a comprehensive literature search of PubMed and Web of Science databases (2015–2026), focusing on stereotactic body radiotherapy (SBRT), oncolytic viruses (OV), and interventional therapies as "inducers," and immune checkpoint inhibitors (ICI), immune-modulating chemotherapy, anti-angiogenic agents, and immune effector cell therapies (CAR-T/TCR-T) as "enhancers." Results: All three inducer modalities activate innate immunity through immunogenic cell death (ICD), yet single-agent abscopal rates remain below 15%. Upon combination with enhancers, SBRT plus ICI demonstrates the most robust evidence (abscopal rates 20–35%), while OV plus ICI shows efficacy in ICI-resistant populations (STOMP trial: 75% clinical benefit). Immune effector cell therapies, particularly CAR-T/TCR-T, represent the next-generation enhancers capable of overcoming solid tumor infiltration barriers when empowered by local treatments, with preclinical data demonstrating macrophage- and T cell-mediated abscopal responses following sCAR-T plus microwave ablation or OV plus CAR-T combinations. Conclusion: The "local induction plus systemic enhancement" framework represents a promising and evidence-supported strategy for achieving abscopal effects in clinical practice. ICI serves as the most universally applicable "accelerant," whereas CAR-T/CAR-NK/TCR-T therapies embody a highly promising future direction. Individualized decision-making based on MSI status, antigen heterogeneity, and treatment line remains the cornerstone of successful clinical translation.

  Key words: Abscopal effect; stereotactic body radiotherapy; oncolytic virus; interventional therapy; immune checkpoint inhibitor; CAR-T; combination therapy

  提交时间：2026-06-23

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 张林, 侯艳红, 吴凯, 张静. 立体定向放疗联合免疫治疗在晚期胃肠癌中的远隔效应：一项回顾性研究. 2026. doi: 10.12201/bmr.202606.00027

  张志迪. 淋巴瘤CAR-T细胞治疗患者支持性照护方案的构建. 2025. doi: 10.12201/bmr.202502.00029

  秦晓宇, 樊湘珍, 撒焕兰, 李晓寒, 王明月, 李润宇, 丁舒童, 宁方玲. 抗血管生成药物在免疫治疗时代下应用于晚期非小细胞肺癌一线治疗的研究进展. 2026. doi: 10.12201/bmr.202605.00079

  戴丽君, 杨伟力, 陈延茹. 儿童先心病介入治疗中导管室的风险管理措施. 2025. doi: 10.12201/bmr.202503.00062

  艾俊宇, 杨德林. 前列腺癌关键基因诊疗策略的前沿进展. 2025. doi: 10.12201/bmr.202501.00014

  李颖, 王晓妃, 陆圣威, 董丹妮, 张景峰, 郑建军. 免疫检查点抑制剂相关性肺炎CT表现与临床特点分析. 2024. doi: 10.12201/bmr.202407.00008

  郑歆. PD-1免疫诱导治疗在不可切除Ⅲ期NSCLC中的研究进展. 2025. doi: 10.12201/bmr.202501.00025

  陈海峰, 钱韵. 免疫检查点抑制剂相关不良反应：临床表现与发生机制. 2025. doi: 10.12201/bmr.202502.00010

  王辰晨, 黄学宽, 吴斌. 基于“补肾序贯疗法”治疗SLE经验. 2025. doi: 10.12201/bmr.202507.00053

  雷亚典, 王海燕. 肿瘤免疫微环境影响T细胞的功能：聚焦ICB的局限性和联合治疗方案. 2024. doi: 10.12201/bmr.202412.00083

• 序号	提交日期	编号	操作
  1	2026-06-15	10.12201/bmr.202606.00053V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论